International Journal of Hematology

, Volume 97, Issue 3, pp 345–350 | Cite as

Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases

  • Koji Habe
  • Hideo Wada
  • Takeshi Matsumoto
  • Kohshi Ohishi
  • Makoto Ikejiri
  • Kimiko Matsubara
  • Tatsuhiko Morioka
  • Yuki Kamimoto
  • Tomoaki Ikeda
  • Naoyuki Katayama
  • Tsutomu Nobori
  • Hitoshi Mizutani
Original Article

Abstract

Antiphospholipid antibodies (aPL) including lupus anticoagulant (LA), anticardiolipin antibodies (aCL) IgG and aCL-β2-glycoprotein I (β2GPI) complex IG are causative factors for thrombotic event (THE). We retrospectively investigated relationships between aPLs and THE in 458 patients suspected of having antiphospholipid syndrome. THEs were observed in 232 of 458 patients, including 148 cases of venous thrombosis, 59 of arterial thrombosis, 18 of microthrombosis, and 20 of complications of pregnancy. The frequency of THE was significantly high in patients positive for LA and/or aPL. In patients with autoimmune disease (AID), the frequency of THE was significantly high in patients with any types of aPLs. Additionally, risk of THE was significantly increased in patients with more than two types of aPLs. Prolonged activated partial thromboplastin time indicated a high risk for THE. However, neither thrombocytopenia nor AID was a risk for THE. In conclusion, the presence of aPL is an indicator for high risk of THE in patients in whom THE was suspected. However, the risk of THE in aPL-positive patients varied among patients with different underlying diseases.

Keywords

APS Thrombosis aPL LA β2-Glycoprotein I 

References

  1. 1.
    Palomo IG, Segovia FM, Alarcon ML, Fuentes BY, Pereira JG, Rojas A, Forastiero R. An insight into the pathophysiology of thrombosis in antiphospholipid syndrome. Front Biosci. 2007;12:3093–103.PubMedCrossRefGoogle Scholar
  2. 2.
    Staub HL, Bertolaccini ML, Munther MA: Anti-phosphatidyl- ethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun. Rev. 2012;52:804–10.Google Scholar
  3. 3.
    Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010;19:406–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Hughes G. Hughes Syndrome: the antiphospholipid syndrome–a clinical overview. Clin Rev Allergy Immunol. 2007;32:3–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Chandramouli NB, Rodgers GM. Management of thrombosis in women with antiphospholipid syndrome. Clin Obstet Gynecol. 2001;44:36–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Boyanovski B, Russeva M, Dobreva G, Ganev V, Mladenova A, Peicheva V, Nikolov K, Baleva M. Protein C Activity in patients with antiphospholipid syndrome. J Clin Rheumatol. 2000;6:239–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47:2170–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12:53–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Samarkos M, Mylona E, Kapsimali V. The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity. Semin Arthritis Rheum. 2012;42:66–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.PubMedCrossRefGoogle Scholar
  11. 11.
    Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am J Hematol. 2012;87:S75–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16:627–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus. 2005;14:499–504.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaburaki J, Kuwana M, Ikeda Y: Anti-cardiolipin-beta2-GPI complex antibodies in idiopathic thrombocytopenic purpura. Intern Med. 1998; 37:796. (author reply 797–8).Google Scholar
  15. 15.
    Muñoz-Rodriguez FJ, Font J, Cervera R, Reverter JC, Tàssies D, Espinosa G, López-Soto A, Carmona F, Balasch J, Ordinas A, Ingelmo M. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum. 1999;29:182–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Jennings I, Kitchen S, Kitchen DP, Woods TA, Walker ID. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories? J Thromb Haemost. 2011;9:2117–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International society on thrombosis and haemostasis (ISTH). Thromb Haemost. 2001;86:1327–30.Google Scholar
  18. 18.
    Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:631–40.Google Scholar
  19. 19.
    Kandiah DA, Krilis SA. Heterogeneity of lupus anticoagulant (LA) antibodies: LA activity in dilute Russell’s viper venom time and dilute kaolin clotting time detect different populations of antibodies in patients with the “antiphospholipid” syndrome. Thromb Haemost. 1998;80:250–7.PubMedGoogle Scholar
  20. 20.
    Pengo V, Denas G, Bison E, Banzato A, Jose SP, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, De Candia E, Montaruli B, Marietta M, Testa S, Barcellona D, Tripodi A, Italian Federation of Thrombosis Centers (FCSA). Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with lupus anticoagulant (LA). Thromb Res. 2010;126:150–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Diz-Küçükkaya R, Hacihanefioğlu A, Yenerel M, Turgut M, Keskin H, Nalçaci M, Inanç M. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98:1760–4.PubMedCrossRefGoogle Scholar
  22. 22.
    De Laat B, Derksen RH, Reber G, Musial J, Swadzba J, Bozic B, Cucnik S, Regnault V, Forastiero R, Woodhams BJ, De Groot PG. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost. 2011;9:149–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Pengo V. APS—controversies in diagnosis and management, critical overview of current guidelines. Thromb Res. 2011;127:S51–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Deng X, Liu X. Reevaluation of predictive value of ACL and anti-2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: from a perspective of a practical world. Rheumatol Int. 2012;32:3881–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Sciascia S, Murru V, Sanna G, Roccatello D, A Khamashta M, Laura Bertolaccini M: Clinical accuracy for diagnosis of Antiphospholipid Syndrome in SLE: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012;10:2512-8.Google Scholar
  26. 26.
    Nojima J. Advanced clinical laboratory studies in the graduate school of medicine—studies on pathogenic mechanisms of anti-phospholipid syndrome. Rinsho Byori. 2009;57:786–92.PubMedGoogle Scholar
  27. 27.
    Fujieda Y, Atsumi T, Amengual O, Odani T, Otomo K, Kato M, Oku K, Kon Y, Horita T, Yasuda S, Koike T. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus. 2012;21:1506–14.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Koji Habe
    • 1
  • Hideo Wada
    • 2
  • Takeshi Matsumoto
    • 3
  • Kohshi Ohishi
    • 3
  • Makoto Ikejiri
    • 2
  • Kimiko Matsubara
    • 1
  • Tatsuhiko Morioka
    • 1
  • Yuki Kamimoto
    • 4
  • Tomoaki Ikeda
    • 4
  • Naoyuki Katayama
    • 5
  • Tsutomu Nobori
    • 2
  • Hitoshi Mizutani
    • 1
  1. 1.Department of DermatologyMie University Graduate School of MedicineMieJapan
  2. 2.Department of Molecular and Laboratory MedicineMie University Graduate School of MedicineTsuJapan
  3. 3.Department of Blood TransfusionMie University Graduate School of MedicineMieJapan
  4. 4.Department of Obstetrics and GynecologyMie University Graduate School of MedicineMieJapan
  5. 5.Department of Hematology and OncologyMie University Graduate School of MedicineMieJapan

Personalised recommendations